Cargando…

Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies

BACKGROUND: Rectal budesonide foam is a second-generation corticosteroid efficacious for active mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. This subgroup analysis examined the impact of baseline oral 5-aminosalicylic acid (5-ASA) on the efficacy and safety of budesonide f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bosworth, Brian P., Sandborn, William J., Rubin, David T., Harper, Joseph R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2016
Materias:	Original Clinical Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949012/ https://www.ncbi.nlm.nih.gov/pubmed/27416045 http://dx.doi.org/10.1097/MIB.0000000000000860

Ejemplares similares

Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis
por: Rubin, David T., et al.
Publicado: (2015)

Rectal budesonide and mesalamine formulations in active ulcerative proctosigmoiditis: efficacy, tolerance, and treatment approach
por: Christophi, George P, et al.
Publicado: (2016)

Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial
por: Kruis, Wolfgang, et al.
Publicado: (2022)

Budesonide Foam for Ulcerative Colitis Patients Experiencing Inadequate Response to Biological Therapy
por: Shibuya, Tomoyoshi, et al.
Publicado: (2019)

Ulcerative Proctitis: An Unusual Case of Intestinal Spirochetosis
por: Baum, Jeffrey, et al.
Publicado: (2022)

Ischemic proctosigmoiditis due to retroperitoneal hematoma
por: Roepstorff, Soeren, et al.
Publicado: (2016)

Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis
por: Lichtenstein, Gary R., et al.
Publicado: (2015)

Long-term safety and efficacy of budesonide in the treatment of ulcerative colitis
por: Iborra, Marisa, et al.
Publicado: (2014)

Mesalazine suppository for the treatment of refractory ulcerative chronic radiation proctitis
por: Wu, Changliang, et al.
Publicado: (2018)

Human Mpox Virus Proctitis With Persistent Rectal Ulcers on Sigmoidoscopy
por: Choy, Alexa M., et al.
Publicado: (2023)

Resolution of Anastomotic Ulceration and Profound Bleeding by Endoscopic Cauterization and Oral Budesonide
por: Xi, Dong, et al.
Publicado: (2023)

Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety
por: Maconi, Giovanni, et al.
Publicado: (2021)

Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial
por: Rubin, David T., et al.
Publicado: (2017)

Corrigendum: Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial
por: Rubin, David T, et al.
Publicado: (2017)

Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis
por: Naganuma, Makoto, et al.
Publicado: (2016)

Middle-term prognosis in patients with ulcerative colitis who achieved clinical and endoscopic remission by budesonide rectal foam
por: Naganuma, Makoto, et al.
Publicado: (2019)

Serum Leucine-Rich α2 Glycoprotein: A Biomarker for Predicting the Presence of Ulcerative Colitis but Not Ulcerative Proctitis
por: Horiuchi, Ichitaro, et al.
Publicado: (2022)

Bowel frequency (night) and urgent defecation are improved by budesonide foam in patients with ulcerative colitis: a retrospective observational study
por: Miyazaki, Ryosuke, et al.
Publicado: (2022)

Induction of clinical and colonoscopic remission of mild–to–moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies
por: Sandborn, W. J., et al.
Publicado: (2015)

Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis
por: Lichtenstein, Gary R.
Publicado: (2015)

Correction: Bowel frequency (night) and urgent defecation are improved by budesonide foam in patients with ulcerative colitis: a retrospective observational study
por: Miyazaki, Ryosuke, et al.
Publicado: (2022)

Expression of Concern: Middle-term prognosis in patients with ulcerative colitis who achieved clinical and endoscopic remission by budesonide rectal foam
Publicado: (2023)

When disease extent is not always a key parameter: Management of refractory ulcerative proctitis
por: Michalopoulos, Georgios, et al.
Publicado: (2021)

Investigation of HPLF-111624 in Modified Experimental Models of Ulcerative Proctitis and Anal Fissure in Rats
por: Onkaramurthy, Mallappa, et al.
Publicado: (2022)

Successful Treatment of Refractory Ulcerative Proctitis in a Pediatric Patient Using Topical Tacrolimus
por: Nowacki, Rélana, et al.
Publicado: (2020)

Local administration of mesenchymal stromal cells is safe and modulates the immune compartment in ulcerative proctitis
por: Ouboter, Laura F., et al.
Publicado: (2023)

Lentinan-Based Oral Nanoparticle Loaded Budesonide With Macrophage-Targeting Ability for Treatment of Ulcerative Colitis
por: Lin, Meisi, et al.
Publicado: (2021)

Ulcerative Proctitis in a Patient With a History of Fecal Microbiota Transplant for Clostridioides difficile Infection
por: Massaro, Michael, et al.
Publicado: (2020)

Oral 5-Aminosalicylate, Mesalamine Suppository, and Mesalamine Enema as Initial Therapy for Ulcerative Proctitis in Clinical Practice with Quality of Care Implications
por: Richter, James M., et al.
Publicado: (2016)

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study
por: Travis, Simon P L, et al.
Publicado: (2014)

Eosinophilic Gastroenteritis-associated Duodenal Ulcer Successfully Treated with Crushed Budesonide
por: Kubo, Kimitoshi, et al.
Publicado: (2020)

Foam surfaces for preventing pressure ulcers
por: Shi, Chunhu, et al.
Publicado: (2021)

Diverting colostomy is an effective procedure for ulcerative chronic radiation proctitis patients after pelvic malignancy radiation
por: Huang, Xiaoyan, et al.
Publicado: (2020)

Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis
por: Mitra, Debanjali, et al.
Publicado: (2012)

Low APACHE II and ASA score predicts survival in patients with perforated peptic ulcer
por: Buck, David Levarett, et al.
Publicado: (2012)

Optimizing use of 5-ASA in the treatment of ulcerative colitis: Focus on patient compliance and adherence
por: Bernick, Steven J, et al.
Publicado: (2010)

Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis
por: Louis, Edouard, et al.
Publicado: (2022)

Efficacy and safety of oral beclomethasone dipropionate and budesonide MMX versus 5-aminosalicylates or placebo in ulcerative colitis: a systematic review and meta-analysis
por: Barberio, Brigida, et al.
Publicado: (2023)

Predictive factors for achievement of mucosal healing by budesonide 2-mg foam in ulcerative colitis: a pooled analysis of data from two clinical trials
por: Hibi, Toshifumi, et al.
Publicado: (2020)

Preparation and characterization of pH-sensitive nanoparticles of budesonide for the treatment of ulcerative colitis
por: Zhou, Hong, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4baqot08efieqk2cn6t0eq0vms